VaxiFlu Composition – WHO 2026 Recommended Strains
🌎 WHO 2026 Recommended Strains (Per 0.5 mL Dose – ≥15 µg HA each):
H1N1 – A/Missouri/11/2025 (H1N1)pdm09 H3N2 – A/Singapore/GP20238/2024 B/Victoria – B/Austria/1359417/2021VaxiFlu is an Inactivated Influenza (Split Virion) Trivalent vaccine by Zydus Lifesciences, formulated with WHO recommended strains for 2026. A single 0.5 mL intramuscular dose protects against three influenza strains — H1N1 (A/Missouri), H3N2 (A/Singapore) and B/Victoria lineage (B/Austria). The split virion technology ensures the virus is fully inactivated and fragmented, providing effective immunity with minimal side effects. Since influenza strains change every year, annual vaccination is essential.
At high risk of severe flu. Children under 9 getting first-ever flu vaccine need 2 doses 4 weeks apart.
Weakened immune systems; most vulnerable to severe flu and pneumonia. Annual vaccination critical.
Recommended in any trimester. Maternal antibodies protect newborn for first 6 months of life.
High occupational risk. Annual vaccination protects staff & vulnerable patients simultaneously.
Asthma, COPD, diabetes, heart/kidney disease — all increase risk of severe flu complications.
Travel exposes you to different flu strains. Vaccinate at least 2 weeks before departure.
Reduce sick days and protect vulnerable family members. Annual flu shot recommended for all adults.
HIV, cancer patients on chemo, transplant recipients — all at very high risk. Inactivated vaccine is safe.
| Component | Quantity | Notes |
|---|---|---|
| ACTIVE INGREDIENTS – WHO 2026 STRAINS | ||
| A/Missouri/11/2025 (H1N1)pdm09-like strain | ≥ 15 µg HA | Influenza A (H1N1) – pandemic lineage |
| A/Singapore/GP20238/2024 (H3N2)-like strain | ≥ 15 µg HA | Influenza A (H3N2) – seasonal strain |
| B/Austria/1359417/2021 (B/Victoria lineage)-like strain | ≥ 15 µg HA | Influenza B – Victoria lineage |
| PRODUCTION METHOD | ||
| Propagation medium | Fertilized hen's eggs | From healthy, monitored chicken flocks |
| Inactivation method | Betapropiolactone | Split virion – virus fragmented post-inactivation |
| Group | Dose | Timing | Notes |
|---|---|---|---|
| Children 6 months–8 years (1st ever flu vaccine) | 2 Doses | 4 weeks apart | Single dose annually thereafter |
| Children 6 months–8 years (previously vaccinated) | 1 Dose | Annually | If received ≥2 lifetime flu vaccine doses |
| Children 9 years – Adults | 1 Dose | Every year | Annual single dose regardless of prior vaccination |
| Pregnant women | 1 Dose | Any trimester · annually | Protects mother & transfers antibodies to newborn |
| High-risk adults (65+, chronic disease) | 1 Dose | Annually (before monsoon or winter) | Do not delay – vaccinate as soon as available |
0.5 mL of VaxiFlu is injected into the deltoid muscle. The dose delivers fragmented (split virion) influenza particles from all 3 WHO 2026 strains — H1N1, H3N2 and B/Victoria — each contributing ≥15 µg of Haemagglutinin (HA) antigen. No live virus is present, so the vaccine cannot cause influenza.
Antigen-presenting cells at the injection site process the split virion fragments and present them to T-helper cells, triggering the adaptive immune response against all 3 strains.
B-lymphocytes produce high-titre, strain-specific IgG antibodies targeting H1N1, H3N2 and B/Victoria, which neutralize the virus on future exposure.
Protective antibody levels build up within 10–14 days. Immunity wanes over 6–12 months and strains change every season — so annual vaccination with the current season's VaxiFlu formulation is essential.
VaxiFlu is well-tolerated by most patients. Reactions are generally mild and resolve within 1–2 days.
| Feature | VaxiFlu (Zydus) | FLUARIX SH (GSK) | Influvac Tetra (Abbott) |
|---|---|---|---|
| Number of Strains | 3 (TIV – Trivalent) | 3 (TIV – Trivalent) | ✓ 4 (QIV – Quadrivalent) |
| B/Victoria lineage | ✓ Yes | ✓ Yes | ✓ Yes |
| B/Yamagata lineage | ✗ Not included | ✗ Not included | ✓ Yes (exclusive advantage) |
| Antigen Technology | Split Virion | Split Virion (whole fragmented) | Surface Antigen (HA+NA only) |
| HA per strain | ≥15 µg | 15 µg | 15 µg |
| Manufacturer | Zydus Lifesciences | GSK (GlaxoSmithKline) | Abbott India Ltd |
| MRP (per dose) | ₹1,990 | ₹2,499 | ₹2,688 |
| VacciHub Price | ✓ ₹1,948 | ₹2,374 (5% OFF) | ₹2,554 (5% OFF) |
Trained, certified nurses for all age groups — infants, elderly and pregnant women. Proper deltoid IM injection with post-vaccination monitoring.
VaxiFlu transported in validated cold boxes at 2–8°C. Never frozen. Potency of every dose guaranteed from warehouse to your home.
Sourced from authorised Zydus distributors. Current season (2026) strains only. Batch and expiry fully transparent.
Vaccinate the entire family in one home visit — grandparents, parents, children. No multiple clinic trips required.
We set a WhatsApp reminder for your next year’s flu shot automatically — so you never miss a season.
Flexible bookings morning to evening including weekends. Multiple nurses available for large households.
Call +91 92050 04114 to confirm service availability for your specific pincode — same-day slots available in most areas.
Delhi · Gurgaon · Noida · Ghaziabad · Faridabad
Copyright © All Rights Reserved VacciHub by PSTRIDE SOLUTIONS LLP